Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesRecommendations on current approach to gastric cancer
Clinical and Translational Oncology, 09/11/09
Rivera F et al. – Recently a phase III trial has shown a significant improvement in overall survival when trastuzumab is added to cisplatin–capecitabine or cisplatin–5–fluorouracil in patients with HER2+ advanced gastric cancer. Currently, there are several ongoing clinical trials evaluating the role of other new drugs against cellular targets. It would be desirable to incorporate biomarker studies in these trials in order to identify the best treatment for each patient.
Related Articles
CHD5 is down-regulated through promoter hypermethylation in gastric cancer
BMC: Journal of Biomedical Science, 10/26/09
Relevance Score: 71%
Promoter hypermethylation mediates downregulation of thiamine receptor slc19a3 in gastric cancer
Tumor Biology, 10/12/09
Relevance Score: 71%
KAP1 Is Associated With Peritoneal Carcinomatosis in Gastric Cancer
Annals of Surgical Oncology, 11/11/09
Relevance Score: 69%
Management of patients with pregnancy-associated gastric cancer in Japan: a mini-review
International Journal of Clinical Oncology, 10/30/09
Relevance Score: 69%
A Study of Oxidative Stress Parameters in Anti-Helicobacter Pylorus Immunoglobulin G Positive and Negative Gastric Cancer Patients
Yonsei Medical Journal, 10/29/09
Relevance Score: 69%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A Phase I Study of Pegylated Liposomal Doxorubicin and Irinotecan in Patients with Solid Tumors
Chemotherapy, 12/10/09
The Role of Pemetrexed Combined with Targeted Agents for Non-Small Cell Lung Cancer
Current Drug Targets, 12/10/09
Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer
Current Drug Targets, 12/10/09
Sponsor
Article Search
Sponsor
Sponsor